Ocugen, Inc. (OCGN)

NASDAQ: OCGN · IEX Real-Time Price · USD
0.398
+0.008 (2.18%)
Dec 6, 2023, 4:00 PM EST - Market closed
2.18%
Market Cap 100.06M
Revenue (ttm) n/a
Net Income (ttm) -75.52M
Shares Out 256.50M
EPS (ttm) -0.33
PE Ratio n/a
Forward PE 15.22
Dividend n/a
Ex-Dividend Date n/a
Volume 5,447
Open 0.393
Previous Close 0.389
Day's Range 0.390 - 0.399
52-Week Range 0.345 - 1.620
Beta 3.52
Analysts Strong Buy
Price Target 3.50 (+779.62%)
Earnings Date Nov 9, 2023

About OCGN

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410 and OCU410ST for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Dr. Shankar Musunuri M.B.A., Ph.D.
Employees 84
Stock Exchange NASDAQ
Ticker Symbol OCGN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for OCGN stock is "Strong Buy." The 12-month stock price forecast is $3.5, which is an increase of 779.62% from the latest price.

Price Target
$3.5
(779.62% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Ocugen CEO to Present at NobleCon19 – Noble Capital Markets' Nineteenth Annual Emerging Growth Equity Conference

MALVERN, Pa., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell...

8 days ago - GlobeNewsWire

Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST—Modifier Gene Therapy—for Stargardt Disease

MALVERN, Pa., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and ...

27 days ago - GlobeNewsWire

Ocugen Provides Business Update with Third Quarter 2023 Financial Results

Conference Call and Webcast Today at 8:30 a.m. ET OCU400 demonstrated favorable safety and tolerability profile in retinitis pigmentosa (RP) and Leber congenial amaurosis (LCA) subjects Completed dosi...

4 weeks ago - GlobeNewsWire

Ocugen CSO to Participate in 4th Annual Dry AMD Therapeutic Development Summit

MALVERN, Pa., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell...

4 weeks ago - GlobeNewsWire

Ocugen to Host Conference Call on Thursday, November 9 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2023 Financial Results

MALVERN, Pa., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell...

5 weeks ago - GlobeNewsWire

Ocugen Mucosal Vaccine Candidate OCU500 Selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials

MALVERN, Pa., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell...

2 months ago - GlobeNewsWire

Ocugen to Present at the 2023 Cell & Gene Meeting on the Mesa

MALVERN, Pa., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell...

2 months ago - GlobeNewsWire

Ocugen CSO to Participate in 4th Annual Gene Therapy for Ophthalmic Disorders Conference

MALVERN, Pa., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cel...

2 months ago - GlobeNewsWire

Ocugen to Participate in Fireside Chat at Chardan's 7th Annual Genetic Medicines Conference

MALVERN, Pa., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cel...

2 months ago - GlobeNewsWire

Ocugen, Inc. Announces Connie Collingsworth Joins Business Advisory Board

MALVERN, Pa., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cel...

2 months ago - GlobeNewsWire

Ocugen to Participate in Panel at Cantor Fitzgerald Global Healthcare Conference 2023

MALVERN, Pa., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cel...

2 months ago - GlobeNewsWire

Ocugen Announces Positive Clinical Study Update from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)

MALVERN, Pa., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cel...

3 months ago - GlobeNewsWire

Ocugen to Host Virtual Investor & Analyst Event on September 13, 2023

Company to share updated results from ongoing Phase 1/2 trial of OCU400 for the treatment of Retinitis Pigmentosa and Leber Congenital Amaurosis Company to share updated results from ongoing Phase 1/2...

3 months ago - GlobeNewsWire

Ocugen Provides Business Update with Second Quarter 2023 Financial Results

Conference Call and Webcast Tomorrow at 8:30 a.m. ET •  Investigational New Drug (IND) Applications Cleared for Novel Gene Therapies for Geographic Atrophy Secondary to AMD and for Stargardt Disease •...

3 months ago - GlobeNewsWire

Ocugen to Host Conference Call on Tuesday, August 22 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2023 Financial Results

MALVERN, Pa., Aug. 18, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell...

3 months ago - GlobeNewsWire

Ocugen CEO & CSO to Present at 41st Annual AAPI Convention and Scientific Assembly

MALVERN, Pa., June 30, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell...

5 months ago - GlobeNewsWire

Ocugen, Inc. Announces Adjournment of Annual Meeting of Shareholders

MALVERN, Pa., June 09, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell...

6 months ago - GlobeNewsWire

Ocugen, Inc. Announces Business Advisory Board

MALVERN, Pa., June 05, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell...

6 months ago - GlobeNewsWire

Ocugen stock price plummeted: dead cat bounce can't be ruled out

Ocugen (NASDAQ: OCGN) stock price plunged hard on Wednesday after the company unveiled more plans to dilute shareholders. The penny stock retreated to a low of $0.440, the lowest point since 2020.

7 months ago - Invezz

Ocugen, Inc. Announces Pricing of $16.5 Million Public Offering of Common Stock

MALVERN, Pa., May 24, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, an...

7 months ago - GlobeNewsWire

Ocugen, Inc. Announces Proposed Public Offering of Common Stock

MALVERN, Pa., May 23, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, an...

7 months ago - GlobeNewsWire

Ocugen to Present at BIO International Convention 2023

MALVERN, Pa., May 23, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell ...

7 months ago - GlobeNewsWire

Ocugen Provides Business Update with First Quarter 2023 Financial Results

Conference Call and Webcast Today at 8:30 a.m. ET Announced Positive Preliminary Safety and Efficacy Results from the Phase 1/2 Trial of OCU400 for the Treatment of Retinitis Pigmentosa (RP) and Leber...

7 months ago - GlobeNewsWire

Ocugen to Host Conference Call on Friday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2023 Financial Results

MALVERN, Pa., April 28, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cel...

7 months ago - GlobeNewsWire

Ocugen Announces OCU410ST Receives Orphan Drug Designation for Treatment of ABCA4-Associated Retinopathies

U.S. Food & Drug Administration (FDA) grants orphan drug designation to OCU410ST for the treatment of ABCA4-associated retinopathies including Stargardt, RP19 and CORD3 U.S. Food & Drug Administration...

8 months ago - GlobeNewsWire